Palivizumab biosimilar - CelltrionAlternative Names: CT P14
Latest Information Update: 12 Jun 2015
At a glance
- Originator Celltrion
- Class Antivirals; Monoclonal antibodies
- Mechanism of Action Viral fusion protein inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- No development reported Respiratory syncytial virus infections
Most Recent Events
- 20 Feb 2015 No development reported for Respiratory syncytial virus infections in South Korea (unspecified route) (Celltrion financial report, June 2015)